Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction alpha-1 protein (Cx43) mRNA is the transcript of the GJA1 gene, encoding the most prevalent gap junction protein in the human body (UniProt P17302). Cx43 is essential for forming intercellular channels that allow the passage of ions and small metabolites, playing a vital role in cardiac conduction and skin wound healing (PubMed: 19435111). In chronic wounds, such as diabetic foot ulcers, Cx43 mRNA and protein are often overexpressed at the wound edge, which inhibits cell migration and promotes inflammation (PubMed: 24511355). Therapeutic targeting of Cx43 mRNA using antisense oligonucleotides (ASOs), like Nexagon (CODA-001), aims to transiently downregulate protein expression to accelerate re-epithelialization and reduce scarring (ClinicalTrials.gov: NCT00820144). This approach leverages the temporary knockdown of the protein to shift the wound environment from a chronic inflammatory state to a regenerative one.
Antisense inhibition of translation via sequence-specific binding to mRNA transcripts, leading to reduced protein synthesis (PubMed: 19435111).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction alpha-1 protein mRNA (Cx43 mRNA) (Cx43 mRNA).